N itric oxide (NO) synthase inhibition by chronic administration of N
-nitro-L-arginine methyl ester (L-NAME) induces a dose-dependent increase in blood pressure (BP) 1, 2 and leads to arterial and organ injuries. 3, 4 This model is characterized by thickening 5 and inflammation 6 of the arterial wall of large arteries and perivascular fibrosis in small arterioles of the heart, 4 the central nervous system, 7 and the kidney. 8 These mechanisms constitute important steps in arterial remodeling occurring in different models of hypertension as well as in human hypertension. 9 Therefore, this model provides a good opportunity to investigate the molecular basis of the arterial wall alterations in response to hypertension and endothelial dysfunction.
The renin-angiotensin system is one of the key effectors during L-NAME-induced hypertension, as attested by the beneficial effects of inhibitors of the renin-angiotensin system. 10, 11 L-NAME administration also induces a nuclear factor-B-dependent vascular inflammation, provoking monocyte adhesion to the vessel wall through induction of monocyte chemotactic protein-1, interleukin-6, and macrophage colony-stimulating factor, 12, 13 and triggers fibrosis of coronary arteries through an increased production of transforming growth factor (TGF)-␤ 1 . 14 The aim of our study was to identify genes implicated in vascular alterations induced during moderate and accelerated hypertension, using the DNA chip technology. The design of our experiment allows a dynamic view of gene expression profiling in large arteries after L-NAME intoxication by studying 2 time points: 15 days of intoxication, at which hypertension is moderate and 30 days of intoxication, at which severe hypertension is observed. We studied aorta rather than small arteries because large arteries allowed us to isolate the media layer from the adventitia, and we focused our study on the aortic tunica media, essentially composed of vascular smooth muscle cells (VSMCs), which constitute the main target of endothelium-derived NO.
We report here that the transcriptional profile of aortic media is deeply modified during accelerated hypertension after L-NAME administration, and we present a large-scale independent validation of the DNA chip technology by real-time reverse transcription-polymerase chain reaction (RT-PCR) applied to the study of vascular tissues from animal models.
Methods
The Methods section is available in the online-only Data Supplement at http://www.circulationaha.org.
Results and Discussion
Body Weight, Heart Weight, BP, and Aortic Media Thickness Significant differences (Ϫ24%, PϽ0.05) in body weights are observed after 30 days of L-NAME administration (Table 1) . Although heart weights are similar across the different groups, the ratio of heart weight to body weight increases gradually after L-NAME intoxication. Long-term administration of L-NAME results in a graduated rise in systolic BP, reaching 187Ϯ4.4 mm Hg (ϩ22%, PϽ0.05) at 15 days of administration and 278Ϯ12 mm Hg (ϩ74%, PϽ0.05) at 30 days. This high level of BP shows the high susceptibility of the Fischer 344 strain of rat to endothelial dysfunction compared with other strains, such as Wistar 6 or SpragueDawley 15 rats.
By morphometric study, we observed that the aortic media thickness gains 40% (PϽ0.05) at day 15 and 35% (PϽ0.05) at day 30 of L-NAME administration (Table 1) , compared with the control group, confirming previous results. 5, 11, 16 Interestingly, the thickening of the media is already significant at day 15 of administration, although BP is moderately increased at that time. Cell counting revealed that the number of VSMCs increases in media after L-NAME intoxication (ϩ25% at day 15 and ϩ21% at day 30, PϽ0.05), showing a proliferation of these cells (data not shown). Cell hypertrophy also occurs because the number of VSMCs by media surface decreases (Ϫ30% at day 15, PϽ0.05, and Ϫ25% at day 30). Thus, simultaneous proliferation and hypertrophy of VSMCs occur in the L-NAME model. Fifteen days later, the thickening is similar, whereas the rats present with severe hypertension. Thus, the moderate rise of BP associated with the NO synthase inhibition seems to be sufficient to deeply modify the aortic structure at day 15. Immunostaining for ED-1 revealed no infiltration of monocytes into aortic wall after L-NAME administration (data not shown).
Analysis of the DNA Chip Data
The arterial remodeling induced by L-NAME is associated with important phenotypic modifications of VSMCs, reinforcing the interest to characterize their transcription profile in our model. By studying the gene expression profile in rat aortic SMCs at 15 and 30 days of L-NAME administration, we showed that the number of modulated genes increases considerably with time and with BP increase. Statistical analysis indicated that the number of differentially expressed genes increases from 53 at day 15 (list available in Data Supplement Table 2 ) to 147 at day 30 (Data Supplement  Table 3 ), and this number is probably inaccurate, because not all genes are present in the DNA chips used and because the sensitivity and specificity of the method are not complete. The significance of this increase is difficult to interpret, but it is likely that, at day 15, genes are directly modulated by BP increase as well as the absence of NO production. NO is known to modulate the transcription of genes owing to its action on transcription factor activity, such as activating protein-1 and nuclear factor-B. 17 At day 30, the high level of BP, with its mechanical and biochemical consequences, is likely to be the major regulatory factor. The persistence of transcriptional regulatory signals throughout L-NAME administration is attested to by the modulation of 28 genes at both day 15 and day 30 ( Table 2 and Data Supplement Table 4 ).
Real-Time PCR Validation of DNA Chip Expression Data
To confirm the changes in gene expression determined by the statistical analysis of the chip data, we performed real-time RT-PCR on a large number of selected genes. Validation by RT-PCR was performed on 2 independent experimental series of rats, a first series used for both the DNA chip and RT-PCR experiments (series 1) and a second series, used only for the RT-PCR experiments (series 2). First, we checked the expression of the genes in rat samples that were also used for the Affymetrix chip experiments to evaluate the validity of Affymetrix data. We measured the expression of all genes modulated at both periods of intoxication (15 and 30 days) and of some genes detected only at 15 or 30 days of ND indicates not determined because of sample availability restriction. The fold changes in mRNA levels of the selected genes were determined by real-time RT-PCR. Values represent fold change of mRNA levels of treated rats compared with control rats after normalization for GAPDH content. Data are mean of 4 to 6 samples per group.
Rat series 1: animals used for DNA chips studies and RT-PCR confirmation. Rat series 2: independent experimental series of animals used for RT-PCR confirmation only. *PϽ0.05 vs controls.
intoxication. All known genes modulated at days 15 and 30 are confirmed (Table 2) , except for 1, the insulin-like growth factor-2 receptor (96% confirmation rate). Thus, there is a close correlation between qualitative changes in mRNA expression detected at 2 time points with the DNA chip and real-time RT-PCR measurements, although the magnitude of the modulation observed varies according to the method used. Genes modulated at just 1 of the 2 intoxication durations according to DNA chip measurements were also confirmed for Ϸ87% of them by RT-PCR (Table 3) . For some genes, RT-PCR measurements showed that they were modulated at both experimental times, suggesting a better sensitivity of this method in these cases. Second, we studied by RT-PCR a large series of genes on an independent series of rats (series 2), not used for the DNA chip experiments, to estimate interexperimental variations. Of all the known genes and unidentified expressed sequence tags modulated at days 15 and 30, 78% are validated by real-time RT-PCR ( Table 2 ). All members of the HSP family that are modulated in the first series of rats are unchanged by L-NAME in the second series. Except for this set of genes, the results corroborate those obtained with the previous rats. This result illustrates one of the drawbacks of the genomic approach, which allows a large number of genes to be studied, even those not related to the experiment and whose expression can be altered by intercurrent experimental factors unavoidable with in vivo experiments. Thus, confirmation on an independent series of animals is mandatory for the genomic approach of in vivo experiments.
Functional Classification of the Regulated Genes
Genes modulated by L-NAME in the aortic media were categorized into 7 general categories (cell division, cell signaling/cell communication, cell structure/motility, cell/ organism defense, gene/protein expression, metabolism, and unclassified) based on the role of known genes, as proposed by Hwang et al 18 (Figures 1 to 3) .
The modulation of effectors belonging to these functional groups highlights 3 main biological pathways that are regulated in aortic media after L-NAME administration ( Figure 4 ) and that are discussed in more detail below. The fold changes in mRNA levels of the selected genes were determined by real-time RT-PCR in rat samples used for DNA chip studies (series 1); values represent fold change of mRNA levels of treated rats compared with control rats after normalization for GAPDH content. Data are mean of 6 samples by group.
Numbers in italics indicate fold changes for genes considered to be unchanged according to statistical analysis of DNA chip data. *PϽ0.05 vs controls.
Figure 1.
Functional distribution of genes regulated in rat aortic media after 15 days of L-NAME administration.
Regulation of Cell Proliferation
We detected, by immunohistochemistry, an increase in the number of proliferating cell nuclear antigen-positive cells in aortic media during L-NAME intoxication ( Figure 5 ), highlighting proliferation of VSMCs. This result explains the increase of the number of VSMCs observed in media, and these changes are concomitant with the modulation of several genes regulating cell proliferation. At 15 days of L-NAME intoxication, upregulation of an important set of genes occurs (CDC-2, CKS-2, cyclin A), which may favor proliferation of VSMCs observed during hypertension. 13 At 30 days, we observe a shift in the upregulation of cyclin A to cyclin G 1 and downregulation of an antiproliferative antigen (B-cell translocation gene 2). Moreover, the upregulation at days 15 and 30 of transcription inhibitors Id1, Id2, and Id3 is of particular interest because Id2 and Id3 promote VSMC proliferation. 19, 20 
Extracellular Matrix Remodeling
Among elements of the extracellular matrix, a group of genes is of interest because they are known to be effectors of the vascular calcification process. At days 15 and 30, osteoadherin, which is a member of the small leucine-rich proteoglycan (SLRP) family described in regulation of mineralization, is downregulated in aortic media. Second, bone sialoprotein II and periostin are transcriptionally activated at days 15 and 30, and their expression is known to be correlated with calcification: the former is upregulated during medial calcification, 21 whereas the latter was originally isolated as an osteoblast-specific factor. 22 We observed, by immunohistochemistry, expression of bone sialoprotein II in aortic media ( Figure 5 ), but we did not detect modulation of its protein level by this method. At day 30 of L-NAME administration, an increased expression of osteopontin, detected at the mRNA level, may act as a counterregulatory mechanism. Osteopontin is a potent inhibitor of vascular calcification 23 identified as being upregulated in aortic smooth muscle cells showing a calcifying phenotype. 24 We observed an increase in the immunostaining against osteopontin at days 15 and 30 ( Figure 5) , showing that stabilization of this effector at a protein level is an earlier event than the increase of its mRNA level, which was detected at day 30. Induction of this inhibitor could explain why we did not detect calcifying lesions in media by Von Kossa staining (data not shown). These results highlight the complexity of the regulation of vascular calcification during severe hypertension.
A second type of modulation involving genes coding for elements of the extracellular matrix occurs, which may actively participate in the fibrosis process. Indeed, vascular fibrosis occurs into the coronary vessels after 4 to 8 weeks of L-NAME intoxication, and this remodeling is associated with an overproduction of TGF-␤, 14 known to induce the synthesis of extracellular matrix proteins. We show that the TGF-␤ pathway is regulated in media with the induction at days 15 and 30 of factors activating the pathway, such as thrombospondin-1, which is an extracellular protein able to bind and activate latent TGF-␤, 25 and the latent transforming growth factor-␤ binding protein-2 (LTBP2), which regulates TGF-␤ signaling. Sinha et al 26 showed that expression of LTBP2 parallels TGF-␤ 1 after an arterial injury. After 30 days, several members of the SLRP family, in addition to osteoadherin, are downregulated: fibromodulin, decorin, and lumican. These compounds may act as natural repressors of fibrosis by their ability to interact with TGF-␤ and to inhibit its activity. 27 Decorin was shown to inhibit the increased production of extracellular matrix induced by TGF-␤ in the kidney. 28 In addition, genes induced by TGF-␤ during fibrosis, 14 such as fibronectin, are upregulated. However, the induction of SMAD6 and SMAD7, which inhibit TGF-␤ signaling, counteracts the signaling of this pathway at day 30.
Regulation of Smooth Muscle Tone
Several modulated genes belonging to the cell signaling and communication class constitute potent regulators of smooth muscle tone. The mRNA level of soluble guanylate cyclase, an important NO target in VSMCs, is already decreased by L-NAME at day 15, corroborating the results obtained in aorta from spontaneously hypertensive rats. 29 Thus, the lack of activation of the enzyme by NO seems to trigger a downregulation of the gene expression. The NO pathway is therefore inhibited both at the level of NO synthesis by L-NAME and by decreased expression of the effector normally activated by NO binding in aortic media. In addition, N G ,N G -dimethylarginine dimethylaminohydrolase, which hydrolyzes methylarginine, an NO synthase inhibitor, is downregulated at day 30 by L-NAME.
At day 30, downregulation of RGS-2 expression could participate in the BP rise, because disruption of this gene results in hypertensive animals. 30 RGS-2 is a target of cGMP-dependent protein kinase I-␣ (an NO effector), which attenuates G protein-coupled receptor signaling, such as the thrombin receptor PAR-1. 31 RGS-2 downregulation and PAR-1 mRNA upregulation after 30 days of NO inhibition could potentiate the vasoconstrictive effect of thrombin in the vascular wall.
Conclusions
Modulation of gene expression, in particular of some effectors we identified, is of primary importance in the arterial remodeling process that occurs during hypertension. The expression profile determined at 2 steps of the evolution of hypertension under L-NAME allows us to observe that the worsening of hypertension is associated with an increasing recruitment of genes, which belong to several biological pathways, explaining the pathological phenotype of the aortic wall.
Second, the interest of the genomic approach is to give an extended view on expression modulation for several functional systems of the cell and avoids the bias of the study of a series of selected genes. In this study, we have demonstrated the complexity of gene regulation in this in vivo model, because the variations in gene expression show the existence of counterregulatory loops or physiological compensatory mechanisms that might allow a limitation of the pathological processes. Figure 5 . Immunohistochemistry of aorta. Aorta sections from control rat, rat receiving L-NAME for 15 days, and rat receiving L-NAME for 30 days were stained immunohistochemically for proliferating cell nuclear antigen (PCNA), bone sialoprotein II (BSPII), and osteopontin (OPN). Barϭ30 m.
